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Staphylococcus aureus is the major subclinical mastitis-causing pathogen in dairy cows.
In some European and Latin American countries, rifaximin (RIF) is a commonly used
therapy at drying off. Phytotherapeutics are alternatives for the treatment of infectious
diseases.Melaleuca armillaris essential oil (EO) has been reported as a good antimicrobial
against S. aureus. The aim of this work was to investigate, in vitro, the combined effect of
EO and RIF to identify a synergic interaction against S. aureus in order to obtain enough
information for subsequent pharmacokinetic/pharmacodynamic studies. The minimum
inhibitory concentrations (MIC) for RIF, EO, and combinations of these against S. aureus
strains were determined at pH 7.4, 6.5, and 5.0, representing intracellular conditions
where S. aureus is usually located. The fractional inhibitory concentration index (FIC)
and the index of antibacterial activity (E) were evaluated. The MIC of EO at pH 7.4 was
25–12.5 µL/mL and decreased with the acidity of the medium. RIF presented a high
antimicrobial activity (0.032µg/mL) against S. aureus regardless of the pH conditions.
Combining RIF with EO, we found a synergic effect. A mix of 0.004µg/mL of RIF and
12.5 µL/mL of EO led to a virtual eradication effect against wild-type strains at pH 7.4.
Media acidification improves the EO/RIF activity, so EO would be a good adjuvant for RIF
to treat staphylococcal infections and decrease antimicrobial resistance.
Keywords: Staphylococcus aureus, dairy cows, Melaleuca armillaris, essential oil, rifaximin, checkerboard,
synergism
INTRODUCTION
The growing threat of antimicrobial resistance to antibiotics has dramatically increased therapeutic
failure and encourages exploring new therapeutic alternatives (1).
Staphylococcus aureus is one of the major contagious pathogens responsible for subclinical
bovine mastitis. It is believed that the intracellular survival of this microorganism contributes to
its recurrence (2). This microorganism is important for public health because of its virulence and
the potential risk of genetic antimicrobial resistance determinants transference among animals,
humans, and the environment (1).
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Plant essential oils (EOs), complex mixtures of secondary
metabolites, together with conventional antibacterials (ABs) may
have synergistic effects (3). The different compounds present at
the same time in plant extracts make it more difficult for the
bacteria to develop simultaneous resistance mechanisms against
each of them (4, 5).
Melaleuca armillaris (Sol. ex Gaertn.) Sm. is one of the most
widely cultivatedMelaleuca plants. Gas chromatography coupled
with mass spectrometry research ofM. armillaris EO revealed the
presence of 1,8-cineol as the main component (6, 7). Inhibitory
activity, in vitro, was found against several bacterial species,
including S. aureus (8).
Difficulties in finding new AB molecules led to exploiting
different strategies in those already in existence (9). Combined
therapy, which associates conventional ABs with natural
compounds such as EOs, represents a promising strategy
to facing resistance to ABs (10). Synergistic combinations
have greater efficacy and lower toxicity than their isolated
components. There are some studies accounting for the
synergistic activity between EOs and ABs (7, 11, 12) which
suggest that the oil has potential to be used as an adjuvant in
antimicrobial therapy.
Rifaximin (RIF) is an AB belonging to the ansamycin group,
developed from rifamycin (13). It acts as an inhibitor of the RNA
synthesis processes (14).
RIF has been traditionally applied in human medicine to
treat travelers’ diarrhea (15, 16) and hepatic encephalopathy (17).
Valentin et al. (18) found rifampicin resistance in Staphylococci.
Rifaximin and rifampicin are analogous. Consequently, RIF
resistance in a microorganism can be compared to rifampicin
resistance (19). Rifampicin resistance is mainly produced by
chromosomal alteration of DNA-dependent RNA polymerase,
which is the AB target (20, 21). There are reports evidencing a
quick in vitro and in vivo resistance development to rifamycins
when these are used as mono-drugs (22, 23). Therefore, it is
usually combined with other compounds (20, 24).
Rifaximin usage in veterinary medicine is indicated for
reproductive disorder treatments for cows and horses (25).
Moreover, this antimicrobial is used as a good alternative to
metronidazole to treat chronic enteropathy in dogs (26) as well
as for localized treatment in bovine mastitis (27, 28). RIF usage
in cows with mastitis has been approved by the European Agency
for the Evaluation of Medicinal Products in Europe and is
widely used in countries such as Italy, France, Poland, Austria,
Estonia, and Israel. On the other hand, this antibiotic is also
being widely used with the same purpose in South America,
mainly in Argentina, Chile, and Uruguay. However, information
about its pharmacodynamic and pharmacokinetic behavior is
non-existent. There are only a few publications on its efficacy in
milk cattle (29, 30).
There are no reports about RIF combined with essential oils.
We previously found a synergic activity between M. armillaris
essential oil and cloxacillin (7).
Thus, the aim of this study was to establish the in vitro
antimicrobial activity of RIF combined with M. armillaris EO
at different pH values (emulating intracellular conditions). This
condition allows us to assess whether this EO is a good adjuvant
for ansamycins in S. aureus treatment within the intracellular
environment where it is usually located.
MATERIALS AND METHODS
M. armillaris Essential Oil Extraction and
Characterization
Leaf and herbaceous branch collection was carried out in Coronel
Brandsen, Buenos Aires, Argentina (latitude 35◦06′18.9′′ S and
longitude 58◦10′57.0′′ W). In July 2015, we obtained 44.85 kg
of plant material. A sample portion was reserved for the
identification and further storage at the LPAG herbarium at
the Faculty of Agrarian and Forestry Sciences, UNLP (31). EO
was obtained by steam distillation of the whole collected fresh
biomass, yielding 550ml of oil. Subsequently, the EO was dried
with sodium sulfate anhydrous at room temperature, filtered
using a cotton funnel, and stored in a glass amber bottle until
use at 4◦C.
The EO composition was analyzed before starting the
antimicrobial assays with gas chromatography–flame ionization
detection–mass spectrometry (GC-FID-MS), as we previously
described (7), in order to avoid any variation in the EO
composition during the storage until use.
S. aureus Strains and Susceptibility
Against RIF
Three wild-type (n = 3) S. aureus, isolated according to the
National Mastitis Council procedure (32), from subclinical
mastitis Holstein cows were used. The protocol was carried out
following the Guide for the Care and Use of Agricultural Animals
in Agricultural Research and Teaching (Federation of Animal
Science Societies, FASS) and was approved by the Institutional
Committee (CICUAL) of the Faculty of Veterinary Sciences,
National University of La Plata (47.3.15J). For quality control,
S. aureus ATCC 29213 was used. S. aureus susceptibility was
checked with the disk diffusion test using rifampicin disk (5 µg)
as a marker for the RIF susceptibility of S. aureus (33).
Minimum Inhibitory and Bactericidal
Concentrations of RIF and EO
The minimum inhibitory concentrations (MICs) of RIF and
EO were determined by the broth microdilution method in
96-well polystyrene microplates. Mueller Hinton Broth (MHB)
culture medium was used with the addition of 0.5% of Tween
80 to improve the EO dissolution. The MICs and minimum
bactericidal concentrations (MBCs) were evaluated at three pH
values (7.4, 6.5, and 5.0) in order to analyze what would happen
at the intracellular level (inside cytosol or phagolysosome) where
S. aureus is internalized. Hydrochloric acid 0.1N for the broth
pH adjustment was applied.
The antibiotic stock solution was prepared by using high-
potency RIF (>99%, w/w; Santa Cruz Biotechnology, CA, USA).
Methanol (Baker-Mallinckrodt, Phillipsburg, USA) was applied
as the solvent and MHB as the diluent. The range of dilutions
assessed was from 256 to 0.007µg/mL using 2-fold serial dilution
(34). In the case of the EO, a range of 50–0.1 µl/mL was tested.
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We applied the same procedure described by CLSI 2009 (34),
with the addition of 0.5% Tween 80 for EO solubilization.
Each plate was inoculated with a final bacterial concentration
of 5 × 105 UFC/ml and incubated at 35◦C for 18–24 h. MIC
was established as the lowest concentration inhibiting bacterial
growth. Positive and negative controls with MHB containing
0.5% Tween 80 were performed. Every determination for each
strain was evaluated at the three different pH conditions
by triplicate.
Once MIC was established, 25 µL was taken from each well-
showing no evident bacterial growth. Then, these were inoculated
individually in nutritive agar plates for colony counting after
incubation at 35◦C for 18–24 h. Thus, MBC was the first
antimicrobial concentration in which the initial inoculum falls
at 99.9%.
Antimicrobial Activity of Combinations of
RIF/EO
Once MIC determinations were established, a checkerboard
technique (35) was carried out for the combinations of RIF and
EO at pH of 7.4, 6.5, and 5.0. This led to establishing the presence
or absence of a synergistic interaction between them against S.
aureus. The microplate design comprised a 2-fold serial dilution
column of RIF with a 2-fold serial dilution row of EO (both MIC
controls). The additional wells contained RIF and EO in different
proportions. The final volume was 200 µL, so it was added 100
µL of broth, 50µL of the correspondent antibiotic concentration,
and the same for the EO. The inocula were dispensed considering
a final concentration of 5 × 105 CFU/ml per well, as for the
MIC determination explained above. Microplates were incubated
at 35◦C for 18–24 h, and every determination was carried out
in triplicate. The results were interpreted by considering the
fractional inhibitory concentration indexes (FICs), where this
index is defined as the sum of the quotients between the MIC
of the single and the combined antimicrobials. In this way,
synergism exists if FIC ≤ 0.5, partial or low synergism (PS) if
0.5 < FIC < 1, indifference or addition (I) if 1 ≤ FIC < 2, and
antagonism (A) if FIC ≥ 2 (35).
Antibacterial Activity Index of Rifaximin
Alone and Combined With EO
Once the MICs of EO, RIF, and their combinations were
identified, the data were used to perform time-kill assays so as to
evaluate the antibacterial activity index (E). Each S. aureus strain
was exposed to different concentrations (0.5, 1, 2, 4, and 8 MICs)
of RIF and EO/RIF combinations. In the last case, the mixture
which had the lowest FIC value was established as the MIC and
the proportions of both components were retained. For quality
control, S. aureus ATCC 29213 was used.
Considering the positive (without antimicrobials) and
negative (without antimicrobials and inocula) controls, seven
tubes were prepared. Each one contained a final volume of 1ml
including MHB with 0.5% Tween 80 (pH 7.4, 6.5, and 5.0),
antimicrobials, and a final inoculum of 5 × 105 colony forming
units (CFU)/ml, depending on the case. Incubations were carried
out at 35◦C. Time-kill curves by bacterial plate count at the
initial time, 2, 4, 8, 12, and 24 h incubating at 35◦C by 24 h were
performed. This assay was carried out in triplicate for each strain.
Thereafter, the results were applied into a CFU/ml vs. time
graph design to evaluate the antibacterial activity index (E). Once
E is assessed, an index vs. antibiotic concentration (Log10) graph
is generated to compare any effect with the presence of EO. The
wild strains were grouped by obtaining an n= 3 (using the mean
of triplicates for each strain). Graphics were plotted using the
GraphPad Prism 6 program.
The E was quantified as the difference between the Log10
values of the number of viable bacteria (in colony forming units
per milliliter) at the initial time (nt-0) and at the end of the test
(nt-24). This is represented in the following equation: E = nt-24
– nt-0. Three theoretical breakpoints were applied to assess E: a)
bacteriostatic effect, E = 0 (there are no changes in the value of
nt-0); b) bactericidal effect, E = −3 (there is a reduction of ≥3
Log10 of nt-0; and c) effect of virtual eradication of bacteria, E =
−4 (there is a reduction of≥4 Log10 (99.99%) with respect to the
Log of nt-0 (36).
RESULTS
After EO extraction, we obtained 550ml of this, which resulted
in a yield of 1.22%, v/w (volume/100 g of fresh material). Table 1
summarizes the compounds found by chromatographic analysis
of the EO (Figure 1 shows the gas chromatogram).
Three wild-type strains (n = 3) and a reference strain (ATCC
29213) of S. aureus were tested against RIF, EO, and their
combinations at pH 7.4, 6.5, and 5.0. The MICs obtained and
the FICs in each pH condition are listed in Table 2. The MBC
obtained for each strain and the pH condition tested for EO and
RIF are shown in Table 3, including the relation MBC/MIC.
The MICs of EO and RIF, shown in Table 2, were used
to perform time-kill assays at pH 7.4, 6.5, and 5.0. In
Figures 2, 4, it is possible to observe the effect of the
different RIF concentrations against the S. aureus strains
(reference and wild type, respectively). The acidity seems to
influence the bactericidal activity. At pH 5.0, concentrations
TABLE 1 | Relative percentage composition of Melaleuca armillaris essential oil
(EO).
Compounds Area (%) Compounds Area (%)
1,8-Cineole 72.3 β-Caryophyllene 0.5
Limonene 7.8 α-Terpinene 0.2
α-Pinene 6.0 trans-β-Ocimene 0.2
Myrcene 2.2 Geranyl acetate 0.2
β-Pinene 2.2 α-Phellandrene 0.1
α-Thujene 1.5 Terpinolene 0.1
p-Cymene 1.4 δ-Terpineol 0.1
Terpinen-4-ol 1.4 Aromandendrene 0.1
α-Terpineol 1.4 Geranyl isobutyrate 0.1
Sabinene 1.0 cis-Calamenene 0.1
γ-Terpinene 0.5 Oxi-Caryophyllene 0.1
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FIGURE 1 | Gas chromatographic profile of the Melaleuca armillaris essential oil used (7).
TABLE 2 | Fractional inhibitory concentration indexes obtained for the EO/RIF combination under different pH conditions vs. individual MICs.





























ATCC 29213 25 0.032 12.5/0.002 0.56 25 0.032 6.25/0.004 0.37 12.5 0.032 3.1/0.004 0.38
SA 13 12.5 0.032 6.25/0.002 0.56 12.5 0.032 3.1/0.008 0.50 6.25 0.032 1.6/0.004 0.38
SA 96 12.5 0.032 6.25/0.002 0.56 12.5 0.032 3.1/0.008 0.50 6.25 0.032 1.6/0.004 0.38
SA 139 12.5 0.032 6.25/0.002 0.56 12.5 0.032 3.1/0.008 0.50 6.25 0.032 1.6/0.004 0.38
MIC, minimum inhibitory concentration; EO, essential oil; RIF, rifaximin; FIC, fractional inhibitory concentration.
TABLE 3 | Minimum bactericidal concentrations (MBC) of EO and RIF at pH 7.4, 6.5, and 5.0 and the relation MBC/MIC in the three conditions.





































ATCC 29213 50 2 0.512 16 50 2 0.512 16 25 2 0.064 2
SA 13 25 2 0.512 16 25 2 0.512 16 25 4 0.128 4
SA 96 50 4 0.512 16 25 2 0.512 16 12.5 2 0.128 4
SA 139 25 2 0.512 16 25 2 0.512 16 12.5 2 0.128 4
MIC, minimum inhibitory concentration; EO, essential oil; RIF, rifaximin; MBC, minimum bactericidal concentrations.
of 4 and 8 MIC of RIF had a stronger antimicrobial
effect after 24 h with respect to the situation at pH 7.4.
The addition of EO improves the antimicrobial activity
of RIF, requiring less concentration of it for the same
effect against the reference (Figure 3) and wild-type strains
(Figure 5).
Data obtained from the time-kill assays were used to establish
the antibacterial activity index (E). Figures 6, 7 show the E
vs. Log10 (RIF concentration) and highlight again the synergic
antibacterial effect obtained by the addition of EO to the culture
with RIF against S. aureus (reference and wild-type strains,
respectively). In this way, it is possible to observe that the amount
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FIGURE 2 | Time-kill curve for rifaximin on Staphylococcus aureus ATCC 29213 at pH 7.4 (A), 6.5 (B), and 5.0 (C) [minimum inhibitory concentration (MIC) =
0.032µg/mL].
FIGURE 3 | Time-kill curve for combinations of essential oil/rifaximin on Staphylococcus aureus ATCC 29213 at pH 7.4 (A), 6.5 (B), and 5.0 (C) [minimum inhibitory
concentration (MIC) = 0.032µg/mL].
of RIF necessary to decrease the bacterial inoculum in 24 h is
lower in the presence of EO.
DISCUSSION
EO Extraction and Characterization
Chromatographic analysis of the EO revealed the presence
of 1,8-cineol as the main component (72.3%) and, in lesser
magnitude, limonene (7.8%) and α-pinene (6.0%). These
chemical compounds are commonly present in EOs with high
antimicrobial activity, particularly 1,8-cineol. This compound is
a cyclic monoterpene and is, in general, the main component in
the essential oil of Eucalyptus species (37). In several studies, 1,8-
cineol has also been reported as the main component of the EO
of M. armillaris: 33.9% in Egypt, 85.8% in Tunisia, and 80.2% in
Brazil (38–40). However, these results do not agree with other
authors such as Amri et al. (8) and Siddique et al. (41), who
determined markedly low concentrations of 1,8-cineol: 3.6% and
0.29%, respectively. Two other major compounds present in the
EO with high antimicrobial activity are limonene and α-pinene
(42). These differences are common in aromatic plants and can
be attributed both to genetic varieties and/or exogenous variables.
For these reasons, it is essential that the chemical composition of
the EO we used in this study is shown.
Standardization of the EO composition is very important for
pharmaceutical use. Obtaining clones with their own specific
characteristics would be a probable solution to this issue. This
would facilitate the EO to be used for the establishment of
commercial crops. In this way, the problem of heterogeneity
would be obviated, resulting in the production of homogeneous
EO quality required by market standards. Siani et al. (43)
carried out a vegetative propagation of one chemotype of Lippia
alba cultivated in six different locations in Brazil under several
different environmental conditions. After EO extraction, only
slight variations of the content and qualitative profiles of the
compounds were observed.
On the other hand, it would be possible to obtain some of
the compounds available in the market in case it is necessary to
enrich the obtained EO. This will allow assessing the quality and
efficacy. However, it is necessary to understand which variation
on the composition has an effect on the biological activity to
establish a range of variations without difference.
Inhibitory and Bactericidal Activity of EO
The MIC ofM. armillaris EO against S. aureus ATCC 29213 was
25 µL/mL at pH 7.4 and 6.5, while at pH 5.0 it decreased by half.
This same pattern of antimicrobial activity was observed in all the
wild-type strains tested (SA13, SA96, and SA139); the MIC was
12.5 µL/mL at pH 7.4 and 6.5, decreasing to 6.25 µL/mL when
the pH of the medium was acidified. Something similar occurred
when evaluating the MBC. This parameter decreased between
two and four times at pH 5.0 with respect to pH 7.4 (Table 3).
In addition, the high content of 1,8-cineol may be one of
the factors contributing to the antibacterial activity of the EO.
This compound has been attributed with the permeabilization
of the membranes of microorganisms (such as S. aureus) as an
antimicrobial action due to its high hydrophobicity (44, 45).
Yañez Rueda and Cuadro Mogollón (46) found an important
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antibacterial activity of the Eucalyptus globulus essential oil
against S. aureus ATCC 29213. The MIC was 12.4µg/mL. It
is noteworthy that the composition of the E. globulus EO was
similar to that of the M. armillaris evaluated in this study:
with 1,8-cineol (82.3%), followed by limonene (3.7%), α-pinene
(3.2%), terpinen-4-ol (1.4%), α-terpineol (1.2%), β-myrcene
(1.12%), and α-terpinene (1.1%), among others. Thus, it is
likely that a synergism between these components is particularly
effective against S. aureus strains.
The mechanism of the antimicrobial action of the M.
armillaris EO against S. aureus has not yet been investigated.
Hayouni et al. (47) studied the antimicrobial activity of this plant’s
oil against different species of Lactobacillus. As 1,8-cineol was
the main component found in a concentration of 68.9%, these
authors suggested as a hypothesis that this compound could
have destabilized the bacterial cytoplasmic membrane, as was
demonstrated by Li et al. (48). However, the postulated mode
of action of M. armillaris by Hayouni et al. (47) also involves
a minority of the components found (α-pinene, terpinen-4-ol,
sabinene, β-myrcene, and α-terpinene, among others). According
to these authors, thesemolecules interact with the cell membrane,
where they are dissolved in the phospholipid bilayer and aligned
between the chains of fatty acids. The distortion of the physical
structure would cause the expansion and destabilization of the
membrane, increasing its fluidity, which would increase the
passive permeability.
A compound is bacteriostatic if theMBC/MIC ratio is>4 (49).
The capacity of an EO to act as a bactericidal or bacteriostatic
will depend on the chemical composition of this extract. When
analyzing the MIC and MBC of the EO of M. armillaris against
strains SA13, SA96, and SA139, we found that these parameters
were very close, with a ratio of MBC/MIC ranging between 2
and 4 (Table 3). Therefore, considering the above-mentioned
definition, the EO would act as a bactericidal antimicrobial
maintained with different pH values.
Inhibitory and Bactericidal Activity of RIF
The rifaximin MIC values for quality control to establish
the susceptibility of S. aureus are not included in the CLSI
documents, so we compared our results with the information
published for rifampicin in the CLSI document VET01-S2 (CLSI
2013), which establishes a range of 0.004–0.016µg/mL (it is the
only ansamycin that appears in the document).
A MIC of 0.032µg/mL was obtained for all the studied strains
(reference and wild-type strains). This value is higher than the
value established for rifampicin (0.004–0.016µg/mL) by CLSI
2013 (33). Broth acidification did not produce a variation in the
inhibitory activity of RIF; the MIC was the same at the three pH
values evaluated.
In this study, we observed that RIF had high antimicrobial
activity against the S. aureus strains ATCC 29213, SA13, SA96,
and SA139. The obtained MIC values were similar for all strains
analyzed (0.032µg/mL). This indicates an important antibiotic
potency against S. aureus. Moreover, Hoover et al. (50) found
values ranging between ≤0.015 and 0.03µg/mL for strains of
these types of species, coinciding with our results. In another
study carried out by Pistiki et al. (19), the reported MIC values
of RIF were≤0.25µg/mL. No changes were observed in the MIC
values at different pH levels. However, MBC showed differences
when the antimicrobial activity was analyzed at the most acidic
pH level. The MBC was 0.512µg/mL for all strains at pH 7.4
and 6.5, whereas at pH 5.0 it decreased to 0.064µg/mL for strain
ATCC 29213 and to 0.128µg/mL for the three wild-type strains.
The MBC/MIC for all the analyzed strains was 16 at pH 7.4
and 6.5, working as a bacteriostatic antimicrobial. But at pH 5.0,
the ratio ranged between 2 and 4 (Table 3), meaning that the
antimicrobial activity is bactericidal at a lower pH level.
When we evaluated with the time-kill assay how the presence
of RIF affects the growth of the reference strain of S. aureus,
it was observed that it grew at a concentration of 0.5 MIC
(0.016µg/mL) at the three pH conditions, which was always
lower than the control growth curve (Figure 2). Concentrations
of 2, 4, and 8 MIC showed curves with similar profiles,
independently of the broth pH. The concentrations evaluated
(0.016–0.256µg/mL) allowed us to obtain a decrease of at least 3
Log10 of the initial inoculum at pH 7.4 and 6.5. In contrast, at pH
5.0, the bactericidal effect was achieved for 2, 4, and 8 MIC; this
coincides with the results observed in the determination of MBC
since the values obtained for this parameter were 0.512µg/mL
(pH 7.4 and 6.5) and 0.064µg/mL (pH 5.0).
Something similar was observed for the wild-type strains
SA13, SA96, and 139 (Figure 4) because bactericidal effects were
not seen with the concentrations evaluated at pH 7.4 and 6.5. At
pH 5.0, the initial inoculum decreased more than 3 Log10 with
concentrations of 4 and 8 MIC, corresponding to concentrations
of 0.128 and 0.256µg/mL, respectively. These values were also
consistent with those obtained in the determination of MBC
since, for these strains and at this pH, this value was 0.128µg/mL.
It is possible to observe a reduction in the bacterial count
of S. aureus strains against RIF as early as 2 h after starting the
FIGURE 4 | Time-kill curve for rifaximin on Staphylococcus aureus wild types (n = 3, using the mean of triplicates for each strain) at pH 7.4 (A), 6.5 (B), and 5.0 (C)
[minimum inhibitory concentration (MIC) = 0.032µg/mL].
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time-kill assay. For this antibiotic, it is not yet well-established
whether it is an antimicrobial time- or a concentration-
dependent one. However, some studies report that rifampin
(belonging to the ansamycin family) acts as a concentration-
dependent antimicrobial bactericide (51, 52). On the other hand,
this antibiotic should be combined with other antimicrobials,
such as penicillins resistant to penicillinase, vancomycin, or
trimethoprim, due to it quickly selecting resistant strains when
used as a mono-drug. Resistance to rifampin takes place by
chromosomal mutation and develops easily in most bacteria.
Such mutants show stable changes in the RNA polymerase (the
target site of the antimicrobial action), preventing fixation. These
result from mutations in the rpoB gene, which codes for the sub-
subunit of the bacterial RNA polymers, where these antibiotics
bind (53).
Antimicrobial Activity of EO/RIF
Combinations
In the literature, there are no reports on the combinations
of ansamycins with essential oils against S. aureus. There are
only a few reports of natural extracts with this type of drugs.
For example, Liu et al. (54) found a strong synergistic activity
between rifampicin and manuka honey against strains of S.
aureus-producing biofilm.
Combining RIF with the EO of M. armillaris, a synergistic
effect was found, and the antibiotic activity was enhanced,
particularly at pH 6.5 and 5.0, in all the strains assayed.
At pH 7.4, there were combinations obtained that presented
partial synergism, with FIC = 0.56, very close to the FIC value
considered for synergism (0.5). In this case, it was possible
to decrease, for the four strains studied, 16 times the MIC
of RIF with a decrease to half of the MIC of the EO with
respect to each compound applied alone. At pH 6.5, the decrease
in the inhibitory concentration of the antibiotic was lower
(four times for the wild-type strains and eight times for the
reference strain). However, the drop in the amount of EO
necessary to enhance the antibiotic antimicrobial activity was
more evident here since, for all the strains, the decrease was
four times the MIC of the plant extract. Finally, at pH 5.0, the
MIC of RIF decreased eight times for all strains. In the last
case, the decrease in the inhibitory concentration of the EO is
much more evident since it decreased by a factor of 4 again.
Therefore, as a result of the significant reduction in the inhibitory
concentrations at pH 5.0, both essential oil and antibiotic, the FIC
values obtained were of 0.38, which show an important synergy
between them.
Thus, RIF has a potentiated effect by the sum of two factors:
combination with the essential oil and the acidification of the
culture medium.
In the time-kill assay, we could observe a slow decrease in the
bacterial count for RIF alone that occurs mainly between 12 and
24 h after starting the experiment. On the other hand, when it
was combined with the EO ofM. armillaris, a strong drop in the
bacterial count was observed at 4 h, with a maximum decrease
at 8 h (Figures 3, 5). Moreover, it is evident that the drop of
the slopes of the curves is more important in the presence of
the mixture compared with the EO alone since this produces
the greatest decrease in the viable cell counts at 12 h. Xiao et al.
(55) combined Origanum vulgare essential oil with rifampin,
managing to eliminate S. aureus strains in a stationary phase in
24 h. This effect is different when both compounds act alone,
thus could not kill all the inocula at the same time. Therefore,
combining some essential oils with ansamycins seems to be useful
in treating staphylococcal infections.
In another respect, by analyzing bacteria inoculum decrease
with E (Figures 6, 7), it is possible to graphically observe how
S. aureus is inhibited in a higher magnitude with lower RIF
concentrations when M. armillaris EO is present. This means
that the EO allows a reduction of the amount of necessary
antibiotic for microorganism inhibition. At pH 7.4 and 6.5, RIF
was not able to produce any bactericidal effect on its own at the
tested concentrations, unlike as occurred at pH 5.0, while when
combined with the EO of M. armillaris allowed achieving, with
lower concentrations, bactericidal effects even close to virtual
eradication. For example, a mixture of 0.004µg/mL RIF and 12.5
µL/mL EO allowed achieving a virtual eradication effect against
the wild-type strains at pH 7.4 (Figure 7). Something similar
happened with the reference strain (Figure 6). The acidification
of the media improves the activity of the essential oil/rifaximin
combination. These outcomes are similar to those previously
obtained by combining cloxacillin with EO (7). In both cases,
the acidic conditions increased the synergic effect and the
bactericidal activity, which is interesting if we are dealing with
intracellular infections.
FIGURE 5 | Time-kill curve for combinations of essential oil/rifaximin on Staphylococcus aureus wild types (n = 3, using the mean of triplicates for each strain) at pH
7.4 (A), 6.5 (B), and 5.0 (C) [minimum inhibitory concentration (MIC) = 0.032µg/mL].
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FIGURE 6 | Graphic representation of the antibacterial effect (E: 1Log CFU/ml 24–0 h) of rifaximin against Staphylococcus aureus ATCC 29213 at pH 7.4 (A), 6.5 (B),
and 5.0 (C) in the presence and absence of EO.
FIGURE 7 | Graphic representation of the antibacterial effect (E: 1Log CFU/ml 24–0 h) of rifaximin against Staphylococcus aureus wild type (n = 3, using the mean of
triplicates for each strain) at pH 7.4 (A), 6.5 (B), and 5.0 (C) in the presence and absence of EO.
There are a few studies in vivo with EO; however, Byung-
Wook et al. (56) treated cow’s clinical mastitis with essential
oil of O. vulgare. A decrease in infection by S. aureus without
causing swelling, redness, pain, and heat to the udder has
been observed. There are some essential oil-based products for
intramammary application in the market, such as Phyto-Mast.
This is recommended for intramammary use in lactation and
dry-off. Thymus EO is the antimicrobial active component (57),
and its residues (main component) were only detected 12-h post-
treatment in milk using goats and cows as animal models. The
activity did not present any irritating and inflammatory effects
(58, 59). These findings allow us to consider the feasibility of
administering the essential oil ofM. armillaris intramammary in
the future.
CONCLUSIONS
We observed a reduction of the necessary antibiotic
concentration needed to inhibit S. aureus by combining M.
armillaris essential oil with rifaximin even at different pH
conditions. The in vitro bactericidal activity of the mixture was
very important since, with the RIF/EO mixture, an effect close to
a virtual eradication was obtained.
As was previously mentioned, rifaximin is highly used in
humans and animals and contributes to antimicrobial resistance.
It is known that when rifamycins are used alone, they select
quickly antimicrobial resistance in vivo and in vitro, so it is
required to use them in combination with other compounds to
avoid that effect.
Consequently, we conclude that the essential oil of M.
armillaris could be considered as an effective adjuvant for
therapies with RIF. Nonetheless, it is essential to assess security
by using cell and animal models.
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